Research chemicalResearch chemicalPhenethylaminePsychedelic

TMA-6

Also known as 2,4,6-trimethoxyamphetamine

Written by enwyReviewed 5 Aug 20261 sources0 comments

TMA-6 (2,4,6-trimethoxyamphetamine) is a psychedelic amphetamine of the trimethoxyamphetamine (TMA) series described by Alexander Shulgin in PiHKAL. It is active in the low tens of milligrams, moderately long-acting, and reported to have a strong psychedelic and sometimes stimulating character. Human data is limited to self-experiments and anecdotal reports; there are no controlled studies.

01 Overview

TMA-6 is one of the six positional isomers of trimethoxyamphetamine, distinguished by 2,4,6-methoxy substitution. It is a 5-HT2A agonist and, among the TMA isomers, is reported to be one of the more potent and reliably psychedelic. Shulgin described full psychedelic effects with a substantial duration.

As with the wider TMA family, human knowledge derives almost entirely from PiHKAL and scattered user reports rather than formal pharmacology or toxicology. Some methoxylated amphetamines carry a theoretical MAO-related interaction risk, and overdose can produce an extended and anxious experience; specific toxicology for TMA-6 is essentially uncharacterised.

02 Mechanism

Agonist at serotonin 5-HT2A receptors, the shared mechanism of classical psychedelics; the amphetamine backbone confers potency and moderate duration.

03 Dosing

Tier	Dose	Route	Notes
Threshold	15–25 mg	Oral	Onset of noticeable effects; sensitivity varies.
Common	30–50 mg	Oral	Range reported in PiHKAL; not clinically validated.
Strong	50–70 mg	Oral	Higher doses increase intensity and risk; poorly characterised.

04 Effects

Effect	Magnitude	Evidence
Visual distortionColour enhancement and visual patterning reported by users.	strong	Anecdotal
Altered mood and cognitionEmotional and cognitive shifts typical of serotonergic psychedelics.		Anecdotal
StimulationAmphetamine-like stimulation reported alongside psychedelic effects.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Nausea and body loadGastrointestinal discomfort and body load reported during onset.	Mild	Common	Anecdotal
Anxiety and confusionOverwhelming or frightening experiences, especially with unexpected potency.	Moderate	Common at higher doses	Anecdotal
MAOI interaction riskMethoxylated amphetamines carry a theoretical risk of dangerous interaction with monoamine oxidase inhibitors.	Severe	Rare but potentially severe	Unconfirmed

06 Legal status

United Kingdom

Class A (phenethylamine)

Controlled as a ring-substituted phenethylamine. · as of Jan 2026

United States

Possibly controlled as an analogue

May be treated as a controlled substance analogue under the Federal Analogue Act. · as of Jan 2026

07 References

Shulgin A, Shulgin A. PiHKAL: A Chemical Love StoryTransform Press, 1991

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.